A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome

NCT01008553 | Completed Phase 3 Results

• 2 other identifiers: CR015544JNS020QD-JPN-N02
• Study Type: interventional
• Target: 258
• Locations: 1 country
• Sites: 79

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of fentanyl in opioid-naive participants with post-herpetic neuralgia, complex regional pain syndrome or post-operative pain syndrome who cannot obtain a sufficient analgesic effect by the treatment of non-opioid analgesics (drug used to control pain).

Conditions

Postherpetic Neuralgia; Complex Regional Pain Syndromes (CRPS); Postoperative Pain

Keywords

Postherpetic Neuralgia; Complex Regional Pain Syndromes (CRPS); Postoperative Pain; Fentanyl; Patch, transdermal; Opioid analgesics

Outcome Measures

Primary Outcomes (1)

• Time From the Initial Day of Application in Double-Blind Period to Withdrawal Because of Insufficient Analgesic Efficacy

  Time from start of double-blind (researchers and participants were unaware of the treatment) period to withdrawal because of insufficient analgesic efficacy based on any of the pre-defined discontinuation criteria was noted.

  Day 1 up to Day 85 (double-blind period) and Day 92 (discontinuation of the study)

Secondary Outcomes (12)

• Pain Visual Analog Scale (VAS) Score - Titration Period

  Day 12-14 (Screening period) and Day 27-29 (Titration period)

• Pain Visual Analog Scale (VAS) Score - Double-Blind Period

  Day 27-29 (Titration period) and Day 83-85 (double-blind period)

• Number of Participants Evaluated as Per Participant's Overall Assessment - Titration Period

  Day 1 and 29 or final evaluation (Titration period)

• Number of Participants Evaluated as Per Participant's Overall Assessment - Double-Blind Period

  Day 1 and 85 or final evaluation (double-blind period)

• Number of Doses of Rescue Treatment Per Day - Titration Period

  Day 1 and 29 or final evaluation (Titration period)

Study Arms (3)

Fentanyl (Titration period)

EXPERIMENTAL

One-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will continue for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.

Drug: Fentanyl

Fentanyl (Double-blind period)

EXPERIMENTAL

Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.

Drug: Fentanyl

Placebo (Double-blind period)

PLACEBO COMPARATOR

Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.

Drug: Placebo

Interventions

Fentanyl DRUG

One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.

Fentanyl (Double-blind period); Fentanyl (Titration period)

Placebo DRUG

Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.

Placebo (Double-blind period)

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants whose pain because of post-herpetic neuralgia, Complex Regional Pain Syndrome (CRPS) or post-operative pain syndrome is continuing for at least 12 weeks prior to informed consent
• Participants who are continuously taking a non-opioid analgesic at the normal highest dose or more for at least 14 consecutive days prior to informed consent, or at a certain dose (except the use on an as-needed base) on consecutive days or participants who are continuously taking an analgesic adjuvant with a certain dosage and administration (except the use on an as-needed base) for at least 14 consecutive days prior to informed consent
• Participants showing insufficient therapeutic efficacy of the non-opioid analgesic currently being used, and to requiring a continuous opioid analgesic as per the Investigator or Sub-investigator
• Participants with an average pain intensity of 50 millimeter or more on the Visual Analog Scale in 24-hour daily living prior to informed consent
• Participants who can be hospitalized to the 4th day after the initiation of titration period

You may not qualify if:

• Participants who had an operation that may affect the assessment within 30 days before informed consent
• Participants whose main cause of the pain to be assessed is considered attributable to psychogenic pain (physical pain that is caused, increased, or prolonged by mental, emotional, or behavioral factors)
• Participants with asthma, bradyarrhythmia (slow irregular heart beat) and severe respiratory function disorders
• Participants complicated with hepatic dysfunction such as fulminant hepatitis (inflammation of the liver) and liver cirrhosis (serious liver disorder in which connective tissue replaces normal liver tissue, and liver failure often occurs), or renal impairment such as nephritic syndrome, acute renal failure, and chronic renal failure
• Participants with a history of hypersensitivity to fentanyl and other opioid analgesics

Sponsors & Collaborators

• Janssen Pharmaceutical K.K.: lead

Study Sites (79)

Unknown Facility

Aichi, Japan

Location

Unknown Facility

Amagasaki, Japan

Location

Unknown Facility

Asahikawa, Japan

Location

Unknown Facility

Bunkyō City, Japan

Location

Unknown Facility

Chigasaki, Japan

Location

Unknown Facility

Chūō, Japan

Location

Unknown Facility

Ebetsu, Japan

Location

Unknown Facility

Fujieda, Japan

Location

Unknown Facility

Fujisawa, Japan

Location

Unknown Facility

Fukuoka, Japan

Location

Unknown Facility

Hakodate, Japan

Location

Unknown Facility

Hamamatsu, Japan

Location

Unknown Facility

Hatsukaichi, Japan

Location

Unknown Facility

Higashi-Kitami, Japan

Location

Unknown Facility

Hiratsuka, Japan

Location

Unknown Facility

Hirosaki, Japan

Location

Unknown Facility

Hiroshima, Japan

Location

Unknown Facility

Ichikawa, Japan

Location

Unknown Facility

Ikeda, Japan

Location

Unknown Facility

Isesaki, Japan

Location

Unknown Facility

Itabashi-Ku, Japan

Location

Unknown Facility

Izumo, Japan

Location

Unknown Facility

Kakegawa, Japan

Location

Unknown Facility

Kanazawa, Japan

Location

Unknown Facility

Kasama, Japan

Location

Unknown Facility

Kasuga, Japan

Location

Unknown Facility

Kawasaki, Japan

Location

Unknown Facility

Kita-Gun, Japan

Location

Unknown Facility

Kitakyushu, Japan

Location

Unknown Facility

Kitamoto, Japan

Location

Unknown Facility

Kobe, Japan

Location

Unknown Facility

Kochi, Japan

Location

Unknown Facility

Koga, Japan

Location

Unknown Facility

Komatsu, Japan

Location

Unknown Facility

Koshigaya, Japan

Location

Unknown Facility

Kyoto, Japan

Location

Unknown Facility

Maebashi, Japan

Location

Unknown Facility

Matsumoto, Japan

Location

Unknown Facility

Meguro City, Japan

Location

Unknown Facility

Miki, Japan

Location

Unknown Facility

Minato, Japan

Location

Unknown Facility

Miyazaki, Japan

Location

Unknown Facility

Moriguchi, Japan

Location

Unknown Facility

Morioka, Japan

Location

Unknown Facility

Nagasaki, Japan

Location

Unknown Facility

Nagoya, Japan

Location

Unknown Facility

Niihama, Japan

Location

Unknown Facility

Nishinomiya, Japan

Location

Unknown Facility

Obihiro, Japan

Location

Unknown Facility

Ohmura, Japan

Location

Unknown Facility

Ohta-Ku, Japan

Location

Unknown Facility

Ohtsu N/A, Japan

Location

Unknown Facility

Ohtsu, Japan

Location

Unknown Facility

Okayama, Japan

Location

Unknown Facility

Onomichi, Japan

Location

Unknown Facility

Osaka, Japan

Location

Unknown Facility

Saga, Japan

Location

Unknown Facility

Sakai, Japan

Location

Unknown Facility

Sapporo, Japan

Location

Unknown Facility

Sendai, Japan

Location

Unknown Facility

Setagaya City, Japan

Location

Unknown Facility

Shigenobu N/A, Japan

Location

Unknown Facility

Shimotsuga, Japan

Location

Unknown Facility

Shinagawa City, Japan

Location

Unknown Facility

Suita, Japan

Location

Unknown Facility

Suzaka, Japan

Location

Unknown Facility

Tamaho N/A, Japan

Location

Unknown Facility

Tokushima, Japan

Location

Unknown Facility

Tokyo, Japan

Location

Unknown Facility

Ube, Japan

Location

Unknown Facility

Urayasu, Japan

Location

Unknown Facility

Ureshino, Japan

Location

Unknown Facility

Wakayama, Japan

Location

Unknown Facility

Yachiyo, Japan

Location

Unknown Facility

Yamaguchi, Japan

Location

Unknown Facility

Yamanashi, Japan

Location

Unknown Facility

Yokohama, Japan

Location

Unknown Facility

Yonago, Japan

Location

Unknown Facility

Yūbari, Japan

Location

Related Publications (1)

• Arai T, Kashimoto Y, Ukyo Y, Tominaga Y, Imanaka K. Two placebo-controlled, randomized withdrawal studies to evaluate the fentanyl 1 day patch in opioid-naive patients with chronic pain. Curr Med Res Opin. 2015 Dec;31(12):2207-18. doi: 10.1185/03007995.2015.1092127. Epub 2015 Oct 19.

  PMID: 26359327 DERIVED

MeSH Terms

Conditions

Neuralgia, Postherpetic; Complex Regional Pain Syndromes; Pain, Postoperative

Interventions

Fentanyl

Condition Hierarchy (Ancestors)

Neuralgia; Peripheral Nervous System Diseases; Neuromuscular Diseases; Nervous System Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Autonomic Nervous System Diseases; Postoperative Complications; Pathologic Processes

Intervention Hierarchy (Ancestors)

Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: Director, Clinical Research
• Organization: Janssen Research & Development, L.L.C. USA

1 609 730-3387

Study Officials

• Janssen Pharmaceutical K.K., Japan Clinical Trial

  Janssen Pharmaceutical K.K.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 5, 2009
• First Posted: November 6, 2009
• Study Start: December 1, 2008
• Primary Completion: March 1, 2010
• Study Completion: March 1, 2010
• Last Updated: July 25, 2013
• Results First Posted: July 25, 2013

Record last verified: 2013-06

Locations

JP (79)